Drug General Information (ID: DDIIRK27Q0)
Drug Name			Deferiprone		Drug Info		Lutetium Lu 177 dotatate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Chelating Agents				Therapeutic Radiopharmaceuticals
Structure

Mechanism of Deferiprone-Lutetium Lu 177 dotatate Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Deferiprone				Lutetium Lu 177 dotatate
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Deferiprone and Lutetium Lu 177 dotatate

Recommended Action
Management		Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
3	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."